Jacqueline Cottalorda-Dufayard

Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

R. Garraffo, P. Roger, E. Cua, 2022, Cells.

Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.

J. Izopet, F. Raffi, F. Lucht, 2016, The Journal of antimicrobial chemotherapy.